Symbols / VERU
VERU Chart
About
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 41.89M |
| Enterprise Value | 7.49M | Income | -19.20M | Sales | — |
| Book/sh | 2.31 | Cash/sh | 2.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | — | Forward P/E | -2.17 | PEG | — |
| P/S | — | P/B | 1.13 | P/C | — |
| EV/EBITDA | -0.25 | EV/Sales | — | Quick Ratio | 4.95 |
| Current Ratio | 5.16 | Debt/Eq | 8.02 | LT Debt/Eq | — |
| EPS (ttm) | -1.28 | EPS next Y | -1.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -42.92% |
| ROE | -60.25% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 16.05M |
| Shs Float | 13.48M | Short Float | 5.33% | Short Ratio | 5.50 |
| Short Interest | — | 52W High | 7.40 | 52W Low | 2.10 |
| Beta | -1.49 | Avg Volume | 141.44K | Volume | 53.53K |
| Target Price | $25.00 | Recom | Strong_buy | Prev Close | $2.48 |
| Price | $2.61 | Change | 5.24% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.00
Mean price target
2. Current target
$2.61
Latest analyst target
3. DCF / Fair value
$-12.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.61
Low
$25.00
High
$25.00
Mean
$25.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-18 | init | Canaccord Genuity | — → Buy | $25 |
| 2025-08-13 | main | Raymond James | Outperform → Outperform | $20 |
| 2025-01-02 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-12-20 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-05 | reit | Oppenheimer | Outperform → Outperform | $5 |
| 2024-05-14 | init | B. Riley Securities | — → Buy | $5 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-06 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-15 | reit | Oppenheimer | Outperform → Outperform | $5 |
| 2024-03-28 | init | Raymond James | — → Outperform | $3 |
| 2024-02-08 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-09-27 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-06-07 | up | Jefferies | Underperform → Hold | $1 |
| 2023-05-15 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-05-08 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2023-04-12 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2023-04-06 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2023-03-15 | main | Oppenheimer | — → Outperform | $9 |
| 2023-02-14 | main | Oppenheimer | — → Outperform | $14 |
| 2023-02-10 | main | HC Wainwright & Co. | — → Buy | $14 |
- Oppenheimer reiterates Outperform rating on Veru stock as enobosarm advances - Investing.com hu, 18 Dec 2025 08
- VERU Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More | VERU Stock News - Quiver Quantitative Sat, 13 Dec 2025 08
- Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan Wed, 11 Feb 2026 08
- Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - GlobeNewswire Wed, 17 Dec 2025 08
- Veru Announces Reverse Stock Split - Yahoo Finance Wed, 06 Aug 2025 07
- Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st Wed, 08 Oct 2025 07
- Veru Inc. (VERU) Releases Q4 2025 Earnings: Flat Revenue, EPS Beat Amid Profitability and Cash Pressure - Quiver Quantitative Wed, 17 Dec 2025 08
- Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Wed, 11 Feb 2026 08
- Veru (NASDAQ: VERU) prices offering at $3.00; expected gross proceeds of $25.2M - Stock Titan hu, 30 Oct 2025 07
- Veru And Two Other Penny Stocks To Consider - Yahoo Finance hu, 26 Jun 2025 07
- Veru stock tumbles after pricing public offering at $3 per share - Investing.com hu, 30 Oct 2025 07
- Veru Inc. to Host Conference Call for Fiscal 2026 First Quarter Financial Results and Business Update - Quiver Quantitative Wed, 04 Feb 2026 08
- Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan Wed, 11 Feb 2026 08
- Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative Wed, 11 Feb 2026 11
- One Veru Insider Raised Stake By 150% In Previous Year - Yahoo Finance Sun, 22 Jun 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 150000 | 84351 | — | Purchase at price 0.55 - 0.58 per share. | RANKOWITZ MICHAEL L | Director | — | 2025-02-19 00:00:00 | D |
| 1 | 70183 | 87525 | — | Sale at price 1.23 - 1.39 per share. | STEINER MITCHELL SHUSTER | Chief Executive Officer | — | 2024-05-24 00:00:00 | D |
| 2 | 5000 | 6696 | — | Purchase at price 1.34 per share. | BARNETTE K GARY PH.D. | Officer | — | 2024-05-24 00:00:00 | D |
| 3 | 4000 | 5000 | — | Purchase at price 1.25 per share. | FISCH HARRY | Officer and Director | — | 2024-05-24 00:00:00 | D |
| 4 | 171875 | 246929 | — | Sale at price 1.32 - 1.50 per share. | STEINER MITCHELL SHUSTER | Chief Executive Officer | — | 2024-05-17 00:00:00 | D |
| 5 | 6711 | 9999 | — | Purchase at price 1.49 per share. | FISCH HARRY | Officer and Director | — | 2024-05-15 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 1.01M | 746.97K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.21 |
| NormalizedEBITDA | -54.46M | -38.17M | -94.76M | -82.78M |
| TotalUnusualItems | 19.08M | 1.05M | 4.79M | 3.56M |
| TotalUnusualItemsExcludingGoodwill | 19.08M | 1.05M | 4.79M | 3.56M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.68M | -35.26M | -93.15M | -84.04M |
| ReconciledDepreciation | 152.10K | 268.18K | 269.87K | 209.59K |
| ReconciledCostOfRevenue | 11.03M | 8.73M | 8.76M | 13.33M |
| EBITDA | -35.38M | -37.12M | -89.98M | -79.23M |
| EBIT | -35.53M | -37.39M | -90.25M | -79.44M |
| NetInterestIncome | -607.47K | -2.43M | -4.37M | -4.89M |
| InterestExpense | 607.47K | 2.43M | 4.37M | 4.85M |
| NormalizedIncome | -34.76M | -36.31M | -96.93M | -86.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -22.73M | -37.80M | -93.15M | -84.04M |
| TotalExpenses | 35.53M | 37.39M | 111.90M | 122.84M |
| TotalOperatingIncomeAsReported | -24.75M | -36.17M | -93.78M | -83.49M |
| DilutedAverageShares | 14.65M | 13.49M | 8.50M | 8.01M |
| BasicAverageShares | 14.65M | 13.49M | 8.50M | 8.01M |
| DilutedEPS | -1.55 | -2.80 | -11.00 | -10.50 |
| BasicEPS | -1.55 | -2.80 | -11.00 | -10.50 |
| DilutedNIAvailtoComStockholders | -22.73M | -37.80M | -93.15M | -84.04M |
| NetIncomeCommonStockholders | -22.73M | -37.80M | -93.15M | -84.04M |
| NetIncome | -22.73M | -37.80M | -93.15M | -84.04M |
| NetIncomeIncludingNoncontrollingInterests | -22.73M | -37.80M | -93.15M | -84.04M |
| NetIncomeDiscontinuousOperations | -7.05M | -2.54M | ||
| NetIncomeContinuousOperations | -15.68M | -35.26M | -93.15M | -84.04M |
| TaxProvision | 725.10K | 480.21K | 236.40K | -3.13M |
| PretaxIncome | -15.68M | -35.26M | -92.67M | -83.80M |
| OtherIncomeExpense | 19.85M | 2.13M | 5.36M | 4.05M |
| OtherNonOperatingIncomeExpenses | 768.38K | 1.09M | 573.77K | 495.74K |
| SpecialIncomeCharges | 19.41M | 1.22M | 1.82M | 0.00 |
| GainOnSaleOfPPE | 10.78M | 1.22M | 5.72M | 0.00 |
| GainOnSaleOfBusiness | 0.00 | 18.41M | ||
| OtherSpecialCharges | -8.62M | |||
| ImpairmentOfCapitalAssets | 0.00 | 3.90M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -323.77K | -176.08K | 2.96M | 3.56M |
| NetNonOperatingInterestIncomeExpense | -607.47K | -2.43M | -4.37M | -4.89M |
| TotalOtherFinanceCost | 34.30K | |||
| InterestExpenseNonOperating | 607.47K | 2.43M | 4.37M | 4.85M |
| OperatingIncome | -35.53M | -37.39M | -95.61M | -83.49M |
| OperatingExpense | 35.53M | 37.39M | 103.17M | 114.08M |
| ProvisionForDoubtfulAccounts | 0.00 | 3.91M | -8.50K | |
| ResearchAndDevelopment | 15.59M | 12.78M | 51.20M | 70.91M |
| SellingGeneralAndAdministration | 19.94M | 24.61M | 48.06M | 43.18M |
| GeneralAndAdministrativeExpense | 19.94M | 24.61M | 48.06M | 43.17M |
| OtherGandA | 19.94M | 24.61M | 48.06M | 43.17M |
| GrossProfit | 5.85M | 7.57M | 30.59M | 47.93M |
| CostOfRevenue | 11.03M | 8.73M | 8.76M | 13.33M |
| TotalRevenue | 0.00 | 0.00 | 16.30M | 39.35M |
| OperatingRevenue | 0.00 | 0.00 | 16.30M | 39.35M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TreasurySharesNumber | 218.37K | 218.37K | 218.37K | 218.37K |
| OrdinarySharesNumber | 14.65M | 14.64M | 9.18M | 8.05M |
| ShareIssued | 14.87M | 14.86M | 9.40M | 8.27M |
| NetDebt | 109.27K | |||
| TotalDebt | 3.12M | 13.52M | 14.41M | 15.88M |
| TangibleBookValue | 11.45M | 25.44M | 12.79M | 71.94M |
| InvestedCapital | 18.33M | 42.19M | 29.41M | 93.62M |
| WorkingCapital | 11.13M | 23.36M | 5.12M | 65.29M |
| NetTangibleAssets | 11.45M | 25.44M | 12.79M | 71.94M |
| CapitalLeaseObligations | 3.12M | 3.64M | 4.67M | 5.05M |
| CommonStockEquity | 18.33M | 32.32M | 19.68M | 82.80M |
| TotalCapitalization | 18.33M | 41.17M | 28.55M | 92.45M |
| TotalEquityGrossMinorityInterest | 18.33M | 32.32M | 19.68M | 82.80M |
| StockholdersEquity | 18.33M | 32.32M | 19.68M | 82.80M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -581.52K | -581.52K | -581.52K |
| OtherEquityAdjustments | -581.52K | -581.52K | -581.52K | -581.52K |
| TreasuryStock | 7.81M | 7.81M | 7.81M | 7.81M |
| RetainedEarnings | -317.30M | -294.57M | -256.77M | -163.62M |
| AdditionalPaidInCapital | 343.29M | 335.13M | 283.89M | 253.97M |
| CapitalStock | 148.69K | 148.57K | 939.66K | 826.93K |
| CommonStock | 148.69K | 148.57K | 939.66K | 826.93K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 11.50M | 28.10M | 30.34M | 52.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.72M | 16.23M | 12.53M | 13.85M |
| OtherNonCurrentLiabilities | 1.36M | 4.46M | 29.95K | 18.58K |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 16.07K | ||
| NonCurrentDeferredLiabilities | 0.00 | 81.07K | 63.43K | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 81.07K | 63.43K | |
| LongTermDebtAndCapitalLeaseObligation | 2.36M | 11.76M | 12.50M | 13.75M |
| LongTermCapitalLeaseObligation | 2.36M | 2.91M | 3.63M | 4.09M |
| LongTermDebt | 8.85M | 8.87M | 9.66M | 9.40M |
| CurrentLiabilities | 7.79M | 11.87M | 17.81M | 38.71M |
| OtherCurrentLiabilities | 2.68M | |||
| CurrentDebtAndCapitalLeaseObligation | 758.95K | 1.76M | 1.90M | 2.13M |
| CurrentCapitalLeaseObligation | 758.95K | 736.97K | 1.04M | 957.09K |
| CurrentDebt | 1.03M | 864.62K | 1.17M | 3.24M |
| OtherCurrentBorrowings | 1.03M | 864.62K | 1.17M | 3.24M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.51M | 4.49M | 990.61K | 5.99M |
| PayablesAndAccruedExpenses | 3.52M | 2.93M | 14.92M | 30.60M |
| CurrentAccruedExpenses | 394.53K | 669.68K | 1.99M | 8.60M |
| Payables | 3.12M | 2.26M | 12.93M | 22.00M |
| AccountsPayable | 3.12M | 2.26M | 12.93M | 22.00M |
| TotalAssets | 29.84M | 60.42M | 50.02M | 135.36M |
| TotalNonCurrentAssets | 10.92M | 25.20M | 27.09M | 31.36M |
| OtherNonCurrentAssets | 930.85K | 14.58M | 1.51M | 1.56M |
| NonCurrentDeferredAssets | 12.34M | 12.71M | 12.97M | 13.02M |
| NonCurrentDeferredTaxesAssets | 12.34M | 12.71M | 12.97M | 13.02M |
| GoodwillAndOtherIntangibleAssets | 6.88M | 6.88M | 6.88M | 10.86M |
| OtherIntangibleAssets | 5.95K | 3.98M | 4.05M | |
| Goodwill | 6.88M | 6.88M | 6.88M | 6.88M |
| NetPPE | 3.11M | 3.73M | 5.99M | 5.97M |
| AccumulatedDepreciation | -600.63K | -484.07K | -3.79M | -3.64M |
| GrossPPE | 3.71M | 4.22M | 9.77M | 9.61M |
| Leases | 199.53K | 199.53K | 960.69K | 484.46K |
| OtherProperties | 2.75M | 3.25M | 7.34M | 7.69M |
| MachineryFurnitureEquipment | 765.91K | 765.91K | 1.47M | 1.44M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 18.92M | 35.22M | 22.93M | 104.00M |
| OtherCurrentAssets | 595.25K | 805.63K | 1.10M | 1.96M |
| AssetsHeldForSaleCurrent | 0.00 | 8.76M | ||
| PrepaidAssets | 419.37K | 1.01M | 9.68M | 9.17M |
| Inventory | 4.14M | 6.70M | 8.62M | 5.57M |
| InventoriesAdjustmentsAllowances | -1.58M | -183.79K | -15.71K | -457.49K |
| FinishedGoods | 4.82M | 4.91M | 6.10M | 4.55M |
| WorkInProcess | 79.18K | 112.80K | 872.60K | 112.92K |
| RawMaterials | 827.58K | 1.85M | 1.66M | 1.37M |
| Receivables | 3.96M | 4.51M | 3.55M | 13.79M |
| NotesReceivable | 0.00 | 5.00M | ||
| AccountsReceivable | 3.96M | 4.51M | 3.55M | 8.79M |
| AllowanceForDoubtfulAccountsReceivable | -3.94M | -3.94M | -25.00K | -144.62K |
| GrossAccountsReceivable | 7.90M | 8.45M | 3.58M | 8.94M |
| CashCashEquivalentsAndShortTermInvestments | 18.32M | 25.66M | 9.63M | 80.19M |
| OtherShortTermInvestments | 2.53M | 742.29K | ||
| CashAndCashEquivalents | 15.79M | 24.92M | 9.63M | 80.19M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -30.04M | -21.84M | -88.68M | -48.24M |
| RepaymentOfDebt | 0.00 | -9.09K | -19.43K | |
| IssuanceOfCapitalStock | 0.00 | 35.30M | 6.01M | 0.00 |
| CapitalExpenditure | -1.08K | -158.32K | -665.70K | -733.05K |
| InterestPaidSupplementalData | 332.83K | 704.60K | 554.82K | 2.62M |
| IncomeTaxPaidSupplementalData | 78.55K | 368.82K | 247.36K | 422.13K |
| EndCashPosition | 15.79M | 24.92M | 9.63M | 80.19M |
| BeginningCashPosition | 24.92M | 9.63M | 80.19M | 122.36M |
| ChangesInCash | -9.12M | 15.29M | -70.57M | -42.17M |
| FinancingCashFlow | -4.22M | 36.83M | 11.11M | 1.07M |
| CashFlowFromContinuingFinancingActivities | -4.22M | 36.83M | 11.11M | 1.07M |
| NetOtherFinancingCharges | -4.22M | -132.97K | -130.78K | -137.69K |
| ProceedsFromStockOptionExercised | 0.00 | 1.66M | 5.24M | 1.08M |
| NetCommonStockIssuance | 0.00 | 35.30M | 6.01M | 0.00 |
| CommonStockIssuance | 0.00 | 35.30M | 6.01M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -9.09K | -19.43K | |
| NetLongTermDebtIssuance | 0.00 | -9.09K | -19.43K | |
| LongTermDebtPayments | 0.00 | -9.09K | -19.43K | |
| InvestingCashFlow | 25.14M | 146.21K | 6.33M | 4.27M |
| CashFlowFromContinuingInvestingActivities | 25.14M | 146.21K | 6.33M | 4.27M |
| NetOtherInvestingChanges | 8.28M | 304.54K | 7.00M | |
| NetInvestmentPurchaseAndSale | 393.22K | 0.00 | ||
| SaleOfInvestment | 393.22K | 0.00 | ||
| NetBusinessPurchaseAndSale | 16.47M | 0.00 | 0.00 | 5.00M |
| SaleOfBusiness | 16.47M | 0.00 | 0.00 | 5.00M |
| CapitalExpenditureReported | -1.08K | -158.32K | -665.70K | -733.05K |
| OperatingCashFlow | -30.04M | -21.68M | -88.01M | -47.51M |
| CashFlowFromContinuingOperatingActivities | -30.04M | -21.68M | -88.01M | -47.51M |
| ChangeInWorkingCapital | -4.13M | 222.49K | -15.15M | 26.15M |
| ChangeInOtherCurrentLiabilities | -625.35K | -683.83K | -666.86K | -468.55K |
| ChangeInPayablesAndAccruedExpense | -4.11M | -1.49M | -20.79M | 26.79M |
| ChangeInAccruedExpense | -1.35M | 3.94M | -11.72M | 8.20M |
| ChangeInPayable | -2.76M | -5.43M | -9.07M | 18.59M |
| ChangeInAccountPayable | -2.76M | -5.43M | -9.07M | 18.59M |
| ChangeInPrepaidAssets | 397.57K | 862.04K | 9.81M | -1.58M |
| ChangeInInventory | 863.93K | 986.11K | 648.63K | -3.13M |
| ChangeInReceivables | -657.25K | 546.20K | -4.15M | 4.54M |
| ChangesInAccountReceivables | -657.25K | 546.20K | -4.15M | 4.54M |
| OtherNonCashItems | 471.71K | 673.57K | 2.61M | 2.34M |
| StockBasedCompensation | 8.10M | 13.64M | 17.92M | 11.24M |
| UnrealizedGainLossOnInvestmentSecurities | 323.77K | 176.08K | 0.00 | |
| ProvisionandWriteOffofAssets | -72.83K | 1.57M | 4.10M | 73.52K |
| AssetImpairmentCharge | 0.00 | 3.90M | 0.00 | 0.00 |
| DeferredTax | -1.92K | 367.18K | 177.50K | 76.21K |
| DeferredIncomeTax | -1.92K | 367.18K | 177.50K | 76.21K |
| DepreciationAmortizationDepletion | 152.10K | 268.18K | 269.87K | 209.59K |
| DepreciationAndAmortization | 152.10K | 268.18K | 269.87K | 209.59K |
| OperatingGainsLosses | -12.16M | -799.64K | -8.69M | -3.56M |
| GainLossOnInvestmentSecurities | 3.14M | 239.00K | -2.96M | -3.56M |
| GainLossOnSaleOfPPE | 0.00 | 184.27K | 290.00 | |
| GainLossOnSaleOfBusiness | 4.10M | 0.00 | 0.00 | -18.41M |
| NetIncomeFromContinuingOperations | -22.73M | -37.80M | -93.15M | -84.04M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VERU
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|